PMDA drug package insert
セファメジンα筋注用0.25g
PMDA Prescription drug · LTLファーマ株式会社 · package insert Sep 8, 2026
Key facts
| Brand names | セファメジンα筋注用0.25g, セファメジンα筋注用0.5g |
|---|---|
| Nonproprietary names | セファゾリンナトリウム水和物 |
| Companies | 製造販売／LTLファーマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 合成セファロスポリン製剤 |
| Therapeutic category codes | 876132 |
| YJ codes | 6132401E1040, 6132401E2063 |
| Approval numbers | 21800AMX10149, 21800AMX10150 |
| Package insert edition | 第3版 |
| Package insert date | Sep 8, 2026 |
| PMDA document key | 171911_6132401E1040_4 |
| PMDA company code | 171911 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: